Postoperative chemoendocrine therapy for women with node-positive stage II breast cancer with combined cyclophosphamide, tamoxifen, and 1-hexylcarbamoyl-5-fluorouracil

European Journal of Surgery

Volumn 167, Issue 8, 2001, Pages 598-604

  Tominaga, T ^a   Sano, M ^a   Nishi, T ^a   Sasaki, M ^a   Yoshida, K ^a   Kimura, M ^a   Takashima, S ^a   Asano, T ^a   Yoshida, M ^a   Fujiwara, J ^a   Danno, M ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

1 Hexylcarbamoyl 5 fluorouracil; Breast cancer; Cyclophosphamide; Postoperative chemotherapy; Prognosis; Tamoxifen

Indexed keywords

CARMOFUR; CYCLOPHOSPHAMIDE; TAMOXIFEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TOXICITY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN;

EID: 17944379870     PISSN: 11024151     EISSN: None     Source Type: Journal    
DOI: 10.1080/110241501753171209     Document Type: Article

References (38)

1. Subrenal capsule assay in human breast cancer. Response to cytostatic drug combinations and correlation with receptor status
2. An association between steroid hormone receptors and response to cytotoxic chemotherapy in patients with metastatic breast cancer
3. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: Results of a multicentric Italian study
4. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer
5. Sequential or alterating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results
6. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28, 896 women
7. The Cancer Research Campaign (King's/Cambridge) trial for early breast cancer: Clinicopathological aspects
8. Tamoxifen and chemotherapy for lymphnode-negative, estrogen receptor-positive breast cancer
9. Meeting highlights: International consensus panel on the treatment of primary breast cancer
10. Absorption and excretion of a new oral antitumor drug, 1-hexylcarbamoyl-5-fluorouracil (HCFU), in cancer patients
11. Absorption excretion of a new oral antitumor drug, 1-Hexylcarbamoyl-5-Fluorouracil (HCFU) in cancer patients
12. Antitumor activity of carbamoyl derivatives of 5-fluorouracil by oral administration
13. Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in a variety of experimental tumors
14. Antitumor activity of metabolites of 1-hexylcarbamoyl-5-fluorouracil and related compounds against L1210 leukemia in vivo and L5178Y lymphoma cells in vitro
15. Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumors
16. Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in Lewis lung carcinoma and B16 melanoma
17. Distribution of 1-hexylcarbamoyl-5-fluorouracil and 5-fluorouracil by oral administration in mice
18. Pharmacokinetics of 1-alkylcarbamoyl-5-fluorouracils in plasma and ascites fluid after oral administration in mice
19. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy
20. The general rules for clinical and pathological recording of breast cancer
21. Metabolic fate of 1-hexylcarbamoyl-5-fluorouracil in rats
22. Phase II study of a new fluorinated pyrimidine, 1-hexylcarbamoyl-5-fluorouracil (HCFU)
23. Phase I study of a new antitumor drug, 1-hexylcarbamoyl-5-fluorouracil (HCFU), administered orally: An HCFU Clinical Study Group Report
24. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer
25. 1-Hexylcarbamolyl-5-fluorouracil is more cytostatic than 5-fluorouracil against human tumors in vitro
26. Immunodetection of bone marrow micrometastases in breast carcinoma patients and its correlation with primary tumour prognostic features
27. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration
28. Cerebellar ataxia associated with fluorinated pyrimidine therapy
29. A phase III trial comparing docetaxel and doxorubicin (AT) vs doxorubicin and cyclophosphamide (AC) in first line metastatic breast cancer (MBC)
30. The biology and physiology of 'Nolvadex'* (tamoxifen) in the treatment of breast cancer
31. Endocrine versus endocrine plus five-drug chemotherapy in post-menopausal women with stage II estrogen receptor-positive breast cancer
32. Acute cerebellar syndrome secondary to 5-fluorouracil therapy
33. Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients
34. T. Postoperative chemotherapy for colorectal cancer by combining 5-fluorouracil infusion and 1-hexylcarbamoyl-5-fluorouracil administration after curative resection
35. Blood level of HCFU and clinical results in advanced and metastatic cancer patients
36. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma
37. Effects of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a new antitumor agent for oral use, against recurrent cases of breast cancer
38. Chemotherapy with mitomycin-C and cyclophosphamide adjuvant to surgery for breast cancer